Background—Patients with atrial fibrillation (AF) often take multiple medications. Methods
and Results—We examined characteristics and compared adjusted outcomes between …

Abstract Background Rivaroxaban (20 mg/15 mg once daily) is an effective and safe
alternative to warfarin for stroke prevention in patients with non-valvular AF (NVAF). Low …

Abstract Study Objective Observational studies assessing direct oral anticoagulant (DOACs)
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

We investigated stroke outcomes in normal weight (body mass index [BMI] 18.50 to 24.99
kg/m 2), overweight (BMI 25.00 to 29.99 kg/m 2), and obese (BMI≥ 30 kg/m 2) patients with …

Aims To compare the effectiveness and safety of standard-dose rivaroxaban (20 mg od) and
warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2 …

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage
regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A …

Introduction In the USA, there is a steady rise of atrial fibrillation due to the aging population
with increased morbidity. This study evaluated the risk of stroke/systemic embolism (S/SE) …

Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of
thromboembolism in patients with atrial fibrillation (AF). However, there has been concern …

Background and Purpose: Comparative effectiveness and safety of oral anticoagulants in
patients with atrial fibrillation and high polypharmacy are unknown. Methods: We used …